1. Zhu F#, Zhuang C#, Chu K#, Zhang L#, Zhao H, Huang S, Su Y, Lin H, Yang C, Jiang H, Zang X, Liu D, Pan H, Hu Y, Liu X, Chen Q, Song Q, Quan J, Huang Z, Zhong G, Chen J, Han J, Sun H, Cui L, Li J, Chen Y*, Zhang T*, Ye X*, Li C*, Wu T*, Zhang J*, Xia N-S*. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Respiratory Medicine. 2022;10(8):749-760. (IF 102.64)
2. Zhao F-H#, Wu T#, Hu Y-M#, Wei L-H#, Li M-Q#, Huang W-J#, Chen W#, Huang S-J#, Pan Q-J, Zhang X, Hong Y, Zhao C, Li Q, Chu K, Jiang Y-F, Li M-Z, Tang J, Li C-H, Guo D-P, Ke L-D, Wu X, Yao X-M, Nie J-H, Lin B-Z, Zhao Y-Q, Guo M, Zhao J, Zheng F-Z, Xu X-Q, Su Y-Y, Zhang Q-F, Sun G, Zhu F-C, Li S-W, Li Y-M, Pan H-R, Zhang J*, Qiao Y-L, Xia N-S*. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. The Lancet Infectious Diseases. 2022;22(12): 1756-1768. (IF 71.421)
3. Liu C#, Liu X#, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X*, Liu G*. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nature Nanotechnology. 2022;17(5):531-540. (IF 40.523)
4. Zheng Q#, Zhu R#, Yin Z#, Xu L#, Sun H, Yu H, Wu Y, Jiang Y, Huang Q, Huang Y, Zhang D, Liu L, Yang H, He M, Zhou Z, Jiang Y, Chen Z, Zhao H, Que Y, Kong Z, Zhou L, Li T, Zhang J, Luo W, Gu Y*, Cheng T*, Li S*, Xia N*. Structural basis for the synergistic neutralization of coxsackievirus B1 by a triple-antibody cocktail. Cell Host Microbe. 2022;30(9):1279-1294. (IF 31.316)
5. Wu Y#, Wang S#, Zhang Y#, Yuan L#, Zheng Q#, Wei M#, Shi Y#, Wang Z, Ma J, Wang K, Nie M, Xiao J, Huang Z, Chen P, Guo H, Lan M, Xu J, Hou W, Hong Y, Chen D, Sun H, Xiong H, Zhou M, Liu C, Guo W, Guo H, Gao J, Gan C, Li Z, Zhang H, Wang X, Li S, Cheng T, Zhao Q, Chen Y, Wu T, Zhang T*, Zhang J*, Cao H*, Zhu H*, Yuan Q*, Guan Y*, Xia N*. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19. Cell Host Microbe. 2022(1931-3128 (Print)):T - aheadofprint. (IF 31.316)
6. Wang X#, Sun W#, Shi H, Ma H, Niu G, Li Y, Zhi J, Yao X, Song Z, Chen L, Li S, Yang G, Zhou Z, He Y, Qu S, Wu M, Zhao Z, Yin C, Lin C, Gao J, Li Q, Zhen X, Li L, Chen X, Liu X, An Z, Chen H*, Huang W. Organic phosphorescent nanoscintillator for low-dose X-ray-induced photodynamic therapy. Nature Communications. 2022;13(1):5091. (IF 17.694)
7. Li T#, Chen J#, Zheng Q#, Xue W#, Zhang L#, Rong R, Zhang S, Wang Q, Hong M, Zhang Y, Cui L, He M, Lu Z, Zhang Z, Chi X, Li J, Huang Y, Wang H, Tang J, Ying D, Zhou L, Wang Y, Yu H, Zhang J, Gu Y, Chen Y*, Li S*, Xia N*. Identification of a cross-neutralizing antibody that targets the receptor binding site of H1N1 and H5N1 influenza viruses. Nature Communications. 2022;13(1):5182. (IF 17.694)
8. Wang G#, Zha Z#, Huang P, Sun H, Huang Y, He M, Chen T, Lin L, Chen Z, Kong Z, Que Y, Li T, Gu Y, Yu H, Zhang J, Zheng Q*, Chen Y*, Li S*, Xia N*. Structures of pseudorabies virus capsids. Nature Communications. 2022;13(1):1533. (IF 17.694)
9. Wang W#, Pan D#, Fu W#, Ye X#, Han J, Yang L, Jia J, Liu J, Zhu R, Zhang Y, Liu C, Ye J, Selariu A, Que Y, Zhao Q, Wu T, Li Y, Zhang J*, Cheng T*, Zhu H*, Xia N*. Development of a skin- and neuro-attenuated live vaccine for varicella. Nature Communications. 2022;13(1):824. (IF 17.694)
10. Qin R#, Li S#, Qiu Y#, Feng Y, Liu Y, Ding D, Xu L, Ma X, Sun W, Chen H*. Carbonized paramagnetic complexes of Mn (II) as contrast agents for precise magnetic resonance imaging of sub-millimeter-sized orthotopic tumors. Nature Communications. 2022;13(1):1938. (IF 17.694)
11. Tian R#*, Feng X, Wei L, Dai D, Ma Y, Pan H, Ge S, Bai L, Ke C, Liu Y, Lang L, Zhu S*, Sun H, Yu Y*, Chen X*. A genetic engineering strategy for editing near-infrared-II fluorophores. Nature Communications. 2022;13(1):2853. (IF 17.694)
12. Zhang X#, Hong J#, Zhong L#, Wu Q#, Zhang S#, Zhu Q#, Chen H, Wei D, Li R, Zhang W, Zhang X, Wang G, Zhou X, Chen J, Kang Y, Zha Z, Duan X, Huang Y, Sun C, Kong X, Zhou Y, Chen Y, Ye X, Feng Q, Li S, Xiang T, Gao S, Zeng MS, Zheng Q*, Chen Y*, Zeng YX*, Xia N*, Xu M. Protective anti-gB neutralizing antibodies targeting two vulnerable sites for EBV-cell membrane fusion. Proceedings of the National Academy of Sciences. 2022;119(32):e2202371119. (IF 12.779)
13. Xiong H, Sun H, Wang S, Yuan L, Liu L, Zhu Y, Zhang J, Huang Y, Qi R, Jiang Y, Ma J, Zhou M, Ma Y, Fu R, Yan S, Yue M, Wu Y, Wei M, Wang Y, Li T, Wang Y, Zheng Z, Yu H, Cheng T, Li S*, Yuan Q*, Zhang J*, Guan Y*, Zheng Q*, Zhang T*, Xia N*. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2. Proceedings of the National Academy of Sciences. 2022;119(34):e2204256119. (IF 12.779)
14. Huang Q#, Chen D#, Du C#, Liu Q, Lin S, Liang L, Xu Y, Liao Y*, Li Q*. Highly multiplex PCR assays by coupling the 5'-flap endonuclease activity of Taq DNA polymerase and molecular beacon reporters. Proceedings of the National Academy of Sciences. 2022;119(9):e2110672119. (IF 12.779)
15. Zeng J#, Hong Y#, Zhao N#, Liu Q#, Zhu W#, Xiao L, Wang W, Chen M, Hong S, Wu L, Xue Y, Wang D*, Niu J*, Drlica K, Zhao X*. A broadly applicable, stress-mediated bacterial death pathway regulated by the phosphotransferase system (PTS) and the cAMP-Crp cascade. Proceedings of the National Academy of Sciences. 2022;119(23):e2118566119. (IF 12.779)
16. Wang S#, Sun H#, Zhang Y#, Yuan L#, Wang Y#, Zhang T#, Wang S, Zhang J, Yu H, Xiong H, Tang Z, Liu L, Huang Y, Chen X, Li T, Ying D, Liu C, Chen Z, Yuan Q, Zhang J*, Cheng T*, Li S*, Guan Y*, Zheng Q*, Zheng Z*, Xia N*. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Reports. 2022;39(8):110862. (IF 10)
17. Zhang Y#, Wei M#, Wu Y#, Wang J#, Hong Y#, Huang Y#, Yuan L, Ma J, Wang K, Wang S, Shi Y, Wang Z, Guo H, Xiao J, Yang C, Ye J, Chen J, Liu Y, Fu B, Lan M, Gong P, Huang Z, Su Y, Chen Y, Zhang T, Zhang J, Zhu H, Yu H*, Yuan Q*, Cheng T*, Guan Y*, Xia N*. Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Cell Reports. 2022;38(12):110558. (IF 10)
18. Yang S, Guo X, Zhao Z, Guo Y, Li K, Abudurusuli G, Chen T*. Global differences in natural transmission rates of Monkeypox virus. Journal of Infection. 2022; S0163-4453(22)00502-3. (IF 38.637)
19. Yuan L#, Zhu H#, Wu K, Zhou M, Ma J, Chen R, Tang Q, Cheng T*, Guan Y*, Xia N*. Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model. Signal Transduction and Targeted Therapy. 2022;7(1):47. (IF 38.104)
20. Cheng H, Fan X, Ye E, Chen H, Yang J, Ke L, You M, Liu M, Zhang YW, Wu YL*, Liu G*, Loh XJ*, Li Z*. Dual Tumor Microenvironment Remodeling by Glucose-Contained Radical Copolymer for MRI-Guided Photoimmunotherapy. Advanced Materials. 2022;34(25):e2107674. (IF 32.086)
21. Ju B#*, Zheng Q#, Guo H#, Fan Q#, Li T#, Song S#, Sun H#, Shen S, Zhou X, Xue W, Cui L, Zhou B, Li S*, Xia N, Zhang Z*. Immune escape by SARS-CoV-2 Omicron variant and structural basis of its effective neutralization by a broad neutralizing human antibody VacW-209. Cell Research. 2022;32(5):491-494. (IF 25.617)
22. Bai S, Lan Y, Fu S, Cheng H, Lu Z, Liu G*. Connecting Calcium-Based Nanomaterials and Cancer: From Diagnosis to Therapy. Nano-Micro Letters. 2022;14(1):145. (IF 23.6547)
23. Yuan L#, Zhu H#, Chen P#, Zhou M, Ma J, Liu X, Wu K, Chen R, Liu Q, Yu H, Li L, Wang J, Zhang Y, Ge S, Yuan Q, Tang Q, Cheng T*, Guan Y, Xia N*. Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters. Cellular & Molecular Immunology. 2022;19(12):1392-1399. (IF 22.096)
24. Yuan L, Zhou M, Ma J, Liu X, Chen P, Zhu H, Tang Q, Cheng T*, Guan Y*, Xia N*. Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters. Cellular & Molecular Immunology. 2022;19(2):290-292. (IF 22.096)
25. Chen J#, Wang P#, Yuan L#, Zhang L#, Zhang L#, Zhao H#, Chen C#, Wang X#, Han J#, Chen Y#, Jia J, Lu Z, Hong J, Lu Z, Wang Q, Chen R, Qi R, Ma J, Zhou M, Yu H, Zhuang C, Liu X, Han Q, Wang G, Su Y, Yuan Q, Cheng T, Wu T*, Ye X*, Zhang T*, Li C*, Zhang J*, Zhu H*, Chen Y*, Chen H*, Xia N*. A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin. 2022;67(13):1372-1387. (IF 20.577)
26. Liang X, Cheng H, Liu C, Liu G*. Antigen self-presenting nanovaccine for cancer immunotherapy. Science Bulletin. 2022; 67(16):1611-1613. (IF 20.577)
27. Chen Q, Zhu K, Liu X, Zhuang C, Huang X, Huang Y, Yao X, Quan J, Lin H, Huang S, Su Y#*, Wu T#*, Zhang J, Xia N. The Protection of Naturally Acquired Antibodies Against Subsequent SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. Emerging Microbes & Infections. 2022;11(1):793-803. (IF 19.568)
28. Wang X#*, Yin X#, Zhang B#, Liu C#, Lin Y, Huang X, Li Y, Shen C, Zheng W, Fu G, Chen J, Wen Y, Zhang W, Pan BS, Fang M, Zheng Z, Zhang Z, Yuan Q, Fu G, Li S, Zhang J, Chen Y*, Xia N*, Zhao Q. A prophylactic effect of aluminium-based adjuvants against respiratory viruses via priming local innate immunity. Emerging Microbes & Infections. 2022;11(1):914-925. (IF 19.568)
29. Tang ZM#, Wen GP#, Ying D, Wang SL, Liu C, Tian WK, Wang YB, Fang MJ, Zhou YL, Ge YS, Wu T, Zhang J, Huang SJ*, Zheng ZZ*, Xia NS*. Profile of clinical characteristics and serologic markers of sporadic hepatitis E in a community cohort study. Emerging Microbes & Infections. 2022;12(1):2140613. (IF 19.568)
30. Cai C, Davenport MH*. Prenatal physical activity paradox: occupational versus leisure- time physical activity. British Journal of Sports Medicine. 2022;56(7):365-366. (IF 18.473)
31. Liu X#, Sun X#, Peng Y, Wang Y, Xu D, Chen W, Wang W, Yan X*, Ma X*. Intrinsic Properties Enabled Metal Organic Framework Micromotors for Highly Efficient Self-Propulsion and Enhanced Antibacterial Therapy. ACS Nano. 2022;16(9):14666-14678. (IF 18.028)
32. Bai S#, Lu Z#, Jiang Y, Shi X, Xu D, Shi Y, Lin G, Liu C, Zhang Y*, Liu G*. Nanotransferrin-Based Programmable Catalysis Mediates Three-Pronged Induction of Oxidative Stress to Enhance Cancer Immunotherapy. ACS Nano. 2022;16(1):997-1012. (IF 18.027)
33. Dai Q, Wang L, Ren E, Chen H, Gao X, Cheng H, An Y, Chu C*, Liu G*. Ruthenium-Based Metal-Organic Nanoradiosensitizers Enhance Radiotherapy by Combining ROS Generation and CO Gas Release. Angewandte Chemie International Edition. 2022;61(50):e202211674. (IF 16.823)
34. Ju YY, Shi XX, Xu SY, Ma XH, Wei RJ, Hou H, Chu CC, Sun D, Liu G*, Tan YZ*. Atomically Precise Water-Soluble Graphene Quantum Dot for Cancer Sonodynamic Therapy. Advanced Science (Weinh). 2022;9(19):e2105034. (IF 16.806)
35. Shen H*, Zhang Y, Schramm KW*. Analytical aspects of meet-in-metabolite analysis for molecular pathway reconstitution from exposure to adverse outcome. Molecular Aspects of Medicine. 2022;87:101006. (IF 16.3368)
36. Zeng F, Tang L*, Zhang Q, Shi C, Huang Z, Nijiati S, Chen X, Zhou Z*. Coordinating the Mechanisms of Action of Ferroptosis and the Photothermal Effect for Cancer Theranostics. Angewandte Chemie International Edition. 2022;61(13):e202112925. (IF 15.336)
37. Chen S#, Sun X#, Fu M, Liu X, Pang S, You Y, Liu X, Wang Y, Yan X*, Ma X. Dual-source powered nanomotor with integrated functions for cancer photo-theranostics. Biomaterials. 2022;288:121744. (IF 15.3047)
38. Tang X, Manamanchaiyaporn L, Zhou Q, Huang C, Li L, Li Z, Wang L, Wang J, Ren L, Xu T*, Yan X*, Zheng Y*. Synergistic Integration and Pharmacomechanical Function of Enzyme-Magnetite Nanoparticle Swarms for Low-Dose Fast Thrombolysis. Small. 2022;18(34):e2202848. (IF 15.1536)
39. Zhou H, Lu X, Du C, Zhou Z*, Feng J, Liang Z, Xu Y*, Qiu X*, Shen Z*. Cycloacceleration of Reactive Oxygen Species Generation Based on Exceedingly Small Magnetic Iron Oxide Nanoparticles for Tumor Ferroptosis Therapy. Small. 2022;18(35):e2202705. (IF 15.1536)
40. Lu Z, Bai S, Jiang Y, Wu S, Xu D, Zhang J, Peng X, Zhang H, Shi Y*, Liu G*. Amplifying Dendritic Cell Activation by Bioinspired Nanometal Organic Frameworks for Synergistic Sonoimmunotherapy. Small. 2022:e2203952. (IF 15.1536)
41. Ma X#, Yang S#, Zhang T, Wang S, Yang Q, Xiao Y, Shi X, Xue P, Kang Y, Liu G*, Sun ZJ*, Xu Z*. Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy. Acta Pharmaceutica Sinica B. 2022;12(1):451-466. (IF 14.903)
42. Shi Y#, Qian H#, Rao P#, Mu D, Liu Y*, Liu G*, Lin Z*. Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases. Acta Pharmaceutica Sinica B. 2022;12(3):1126-1147. (IF 14.903)
43. Yuan L#, Zhu H#, Zhou M#, Ma J#, Chen R#, Yu L, Chen W, Hong W, Wang J, Chen Y, Wu K, Hou W, Zhang Y, Ge S, Chen Y, Yuan Q, Tang Q*, Cheng T*, Guan Y*, Xia N*. Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. Protein Cell. 2022;13(1):72-77. (IF 14.8706)
44. Wen X, Shi C, Zeng X, Zhao L, Yao L, Liu Z, Feng L, Zhang D, Huang J, Li Y, Lin Q, Chen H, Zhuang R, Chen X, Zhang X*, Guo Z*. A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti-PD-L1 mAb Combination to Enhance the Antitumor Effect. Clinical Cancer Research. 2022;28(13):2923-2937. (IF 13.801)
45. Zhong Z#, Wang J#, He S#, Su X, Huang W, Chen M, Zhuo Z, Zhu X, Fang M, Li T, Zhang S*, Ge S*, Zhang J, Xia N*. An encodable multiplex microsphere-phase amplification sensing platform detects SARS-CoV-2 mutations. Biosensors and Bioelectronics. 2022;203:114032. (IF 12.545)
46. Ju F#, Luo Y#, Lin C#, Jia X#, Xu Z, Tian R, Lin Y, Zhao M, Chang Y, Huang X, Li S, Ren W, Qin Y, Yu M, Jia J, Han J, Luo W, Zhang J, Fu G*, Ye X*, Huang C*, Xia N*. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. Journal for ImmunoTherapy of Cancer. 2022;10(6) :e004762. (IF 12.469)
47. Bai L#, Hu Z#, Han T, Wang Y, Xu J, Jiang G, Feng X, Sun B, Liu X, Tian R*, Sun H*, Zhang S, Chen X*, Zhu S*. Super-stable cyanine@albumin fluorophore for enhanced NIR-II bioimaging. Theranostics. 2022;12(10):4536-4547. (IF 11.6)
48. Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, Zeng X, Zhang J, Wu X, Zhang X, Miao W, Xu P, Guo Z*, Zhang J, Chen X. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD. Theranostics. 2022;12(16):7180-7190. (IF 11.6)
49. Li S, Zhang Y, Liu X, Tian Y, Cheng Y, Tang L*, Lin H*. Smart NIR-II croconaine dye-peptide for enhanced photo-sonotheranostics of hepatocellular carcinoma. Theranostics. 2022;12(1):76-86. (IF 11.6)
50. Wen X#, Xu P#, Shi M#, Liu J, Zeng X, Zhang Y, Shi C, Li J, Guo Z*, Zhang X*, Khong PL*, Chen X*. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12(1):422-433. (IF 11.6)
51. He P#, Ren E#, Chen B#, Chen H#, Cheng H, Gao X, Liang X, Liu H, Li J, Li B, Chen A, Chu C, Chen X, Mao J*, Zhang Y*, Liu G*. A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma. Theranostics. 2022;12(4):1769-1782. (IF 11.6)
52. Feng Y, Qin R, Xu L, Ma X, Ding D, Li S, Chen L, Liu Y, Sun W, Chen H*. Ion drugs for precise orthotopic tumor management by in situ the generation of toxic ion and drug pools. Theranostics. 2022;12(2):734-746. (IF 11.6)
53. Zhao L#, Niu B#, Fang J#, Pang Y, Li S, Xie C, Sun L, Zhang X, Guo Z*, Lin Q, Chen H*. Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of (68)Ga-Labeled FAPI Dimer. Journal of Nuclear Medicine. 2022;63(6):862-868. (IF 11.082)
54. Ye F, Zhang B, Qiu L, Zhang Y, Zhang Y, Zhang J, Zhao Q*, Lu L*, Zhang Z*. In vivo real-time red blood cell migration and microcirculation flow synergy imaging-surveyed thrombolytic therapy with iron-oxide complexes. Materials Today Bio. 2022;16:100408. (IF 10.761)
55. Du X, Luo L, Huang Q, Zhang J*. Cortex metabolome and proteome analysis reveals chronic arsenic exposure via drinking water induces developmental neurotoxicity through hnRNP L mediated mitochondrial dysfunction in male rats. Science of the Total Environment. 2022;820:153325. (IF 10.753)
56. Xu S, Wu Y, Chen Y, Lu W, Wang YX*, Gao B, Zhang J*. Environmental metal exposure, seminal plasma metabolome and semen quality: Evidence from Chinese reproductive-aged men. Science of the Total Environment. 2022;838(Pt 2):155860. (IF 10.7529)
57. Rui J#, Zheng J-X#, Chen J#, Wei H#, Yu S, Zhao Z, Wang X-Y, Chen M-X, Xia S, Zhou Y*, Chen T*, Zhou X-N*. Optimal control strategies of SARS-CoV-2 Omicron supported by invasive and dynamic models. Infectious Diseases of Poverty. 2022;11(1):115. (IF 10.485)
58. Chen Q#, Yu S#, Rui J#, Guo Y, Yang S, Abudurusuli G, Yang Z, Liu C, Luo L, Wang M, Lei Z, Zhao Q, Gavotte L, Niu Y, Frutos R, Chen T*. Transmissibility of tuberculosis among students and non-students: an occupational-specific mathematical modelling. Infectious Diseases of Poverty. 2022; 11(1):117. (IF 10.485)
59. Li Z#, Cheng H#, Mao J*, Liu G*. Conversion therapy of intermediate and advanced hepatocellular carcinoma using superstable homogeneous iodinated formulation technology. Science China Life Sciences. 2022;65(10):2114-2117. (IF 10.372)
60. Li J, Valkenburgh JV, Fang J, Zhang D, Chen Y, Chen Q, Jia G, Chen AZ, Zhang X*, Chen K*. Development of a novel radiofluorinated riboflavin probe for riboflavin receptor-targeting PET imaging. Pharmacological Research 2022; 183:106395. (IF 10.335)
61. Zeng Y#, Song F#, Luo G#, Yang H, Li C, Liu W, Li T, Zhang S, Wang Y*, Huang C, Ge S*, Zhang J, Xia N. Generation and characterization of mouse monoclonal antibodies against the VP4 protein of group A human rotaviruses. Antiviral Research. 2022; 207:105407. (IF 10.103)
62. Fang J, Feng L, Meng L, Wang X, Liu H, Huang L, Zhang D, Li J, Zhuang R, Guo Z*, Zhang X*. A novel (18)F-labeled agonist for PET imaging of stimulator of interferon gene expression in tumor-bearing mice. European Journal of Nuclear Medicine and Molecular Imaging. 2022;50(1):27-37. (IF 10.057)
63. Zhang Y#, Cheng H#, Chen H#, Xu P, Ren E, Jiang Y, Li D, Gao X, Zheng Y, He P, Lin H, Chen B, Lin G, Chen A, Chu C*, Mao J*, Liu G*. A pure nanoICG-based homogeneous lipiodol formulation: toward precise surgical navigation of primary liver cancer after long-term transcatheter arterial embolization. European Journal of Nuclear Medicine and Molecular Imaging. 2022;49(8):2605-2617. (IF 10.0567)
64. Zhou M#, Wang X#, Chen B#, Xiang S, Rao W, Zhang Z, Liu H, Fang J, Yin X, Deng P, Zhang X*, Hu S*. Preclinical and first-in-human evaluation of (18)F-labeled D-peptide antagonist for PD-L1 status imaging with PET. European Journal of Nuclear Medicine and Molecular Imaging. 2022;49(13):4312-4324. (IF 10.0567)
65. Niu Y, Luo L, Yang S, Abudurusuli G, Wang X, Zhao Z, Rui J, Li Z, Deng B, Liu W, Zhang Z, Li K, Liu C, Li P, Huang J, Yang T, Wang Y, Chen T*, Li Q. Comparison of epidemiological characteristics and transmissibility of different strains of COVID-19 based on the incidence data of all local outbreaks in China as of March 1, 2022. Frontiers in Public Health. 2022;10:949594. (IF 6.461) SSCI
66. Yang Z#, Rui J#, Qi L#, Ye W#, Niu Y#, Luo K, Deng B, Zhang S, Yu S, Liu C, Li P, Wang R, Wei H, Zhang H, Huang L, Zuo S, Zhang L, Zhang S, Yang S, Guo Y, Zhao Q, Wu S, Li Q, Chen Y, Chen T*. Study on the interaction between different pathogens of Hand, foot and mouth disease in five regions of China. Frontiers in Public Health. 2022;10:970880. (IF 6.461) SSCI
67. Zhang L, Fu S, Wang Y, Fang Y*. Research on the optimization of financing scheme of long-term care insurance in China based on system dynamics simulation. Frontiers in Public Health. 2022;10:908864. (IF 6.461) SSCI
68. Yang T#, Wang Y#, Zhao Q#, Guo X, Yu S, Zhao Z, Deng B, Huang J, Liu W, Su Y*, Chen T*. Age-specific transmission dynamic of mumps: A long-term large-scale modeling study in Jilin Province, China. Frontiers in Public Health. 2022;10:968702. (IF 6.461) SSCI
69. Han Y#, Zhang #L, Fang Y#*. Multidimensional Disability Evaluation and Confirmatory Analysis of Older Adults in a Home-Based Community in China. Frontiers in Public Health. 2022;10:899303. (IF 6.461) SSCI
70. Liu W, Guo Z, Abudunaibi B, Ouyang X, Wang D, Yang T, Deng B, Huang J, Zhao B, Su Y, Su C, Chen T*. Model-Based Evaluation of Transmissibility and Intervention Measures for a COVID-19 Outbreak in Xiamen City, China. Frontiers in Public Health. 2022;10:887146. (IF 6.461) SSCI
71. Chiang Y-C*, Li X, Lee C-Y, Wu C-C, Chang H-Y, Zhang S. Effects of Social Attachment on Experimental Drug Use From Childhood to Adolescence: An 11-Year Prospective Cohort Study. Frontiers in Public Health. 2022;10:818894. (IF 6.461) SSCI
72. Yu S#, Cui S#, Rui J#, Zhao Z, Deng B, Liu C, Li K, Wang Y, Yang Z, Li Q*, Chen T*, Wang S*. Epidemiological Characteristics and Transmissibility for SARS-CoV-2 of Population Level and Cluster Level in a Chinese City. Frontiers in Public Health. 2022;9:799536. (IF 6.461) SSCI
73. Li P#, Rui J#, Niu Y#, Xie F, Wang Y, Li Z, Liu C, Yu S, Huang J, Luo L, Deng B, Liu W, Yang T, Li Q*, Chen T*. Analysis of HFMD Transmissibility Among the Whole Population and Age Groups in a Large City of China. Frontiers in Public Health. 2022;10:850369. (IF 6.461) SSCI
74. Li Z#, Lin S#, Rui J#, Bai Y#, Deng B, Chen Q, Zhu Y, Luo L, Yu S, Liu W, Zhang S, Su Y, Zhao B, Zhang H, Chiang YC, Liu J*, Luo K*, Chen T*. An Easy-to-Use Public Health-Driven Method (the Generalized Logistic Differential Equation Model) Accurately Simulated COVID-19 Epidemic in Wuhan and Correctly Determined the Early Warning Time. Frontiers in Public Health. 2022;10:813860. (IF 6.461) SSCI
75. Yang J#, Liao Y#, Hua Q, Sun C, Lv H*. Knowledge, attitudes, and practices toward COVID-19: A cross-sectional study during normal management of the epidemic in China. Frontiers in Public Health. 2022;10:913478. (IF 6.461) SSCI
76. Zhan Y, Han Y, Fang Y*. Socioeconomic Disparities in Disability-Free Life Expectancy and Life Expectancy Among Older Chinese Adults From a 7-Year Prospective Cohort Study. International Journal of Public Health. 2022;67:1604242. (IF 5.1) SSCI
77. Han Y, Sheng Q, Fang Y*. Exploring the Spatial Distribution of Rheumatic Diseases and Its Correlation With Temperature and Humidity Among Middle-Aged and Elderly Adults in China. International Journal of Public Health. 2022;67:1604782. (IF 5.1) SSCI
78. Chiang YC*, Lin YJ#, Li X#, Lee CY#, Zhang S*, Lee TS*, Chang HY*, Wu CC, Yang HJ. Parents' right strategy on preventing youngsters' recent suicidal ideation: a 13-year prospective cohort study. Journal of Mental Health. 2022;31(3):374-382. (IF 3.681) SSCI
79. Xian Li, Lee C-Y, Lin Y-J, Chu M, Qin X, Zhang S, Zhang S*, Chiang Y-C*. Moderating effects of teachers’ praise/criticism on the bullying of vulnerable students among teenagers. Current Psychology. 2022. (IF 2.387) SSCI
80. Kwan ML*, Cheng RK, Iribarren C, Neugebauer R, Rana JS, Nguyen-Huynh M, Shi Z, Laurent CA, Lee VS, Roh JM, Shen H, Rillamas-Sun E, Santiago-Torres M, Hershman DL, Kushi LH, Greenlee H. Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. Journal of Clinical Oncology. 2022;40(15):1635-1646. (IF 44.544)
81. Su J#, Zheng J#, Huang W#, Zhang Y#, Lv C, Zhang B, Jiang L, Cheng T, Yuan Q, Xia N, Zhang J, Li L*, Li L*, Deng X*. PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron. Signal Transduction and Targeted Therapy. 2022;7(1):167. (IF 38.104)
82. Lin X#, Ke X#, Jian X, Xia L, Yang Y, Zhang T, Xiong H, Zhao B, Liu W, Chen Q*, Tang C*. Azacytidine targeting SARS-CoV-2 viral RNA as a potential treatment for COVID-19. Science Bulletin (Beijing). 2022;67(10):1022-1025. (IF 20.577)
83. Qi S, Zhang H, Zhang X, Yu X, Wang Y, Meng Q-F, Yang K, Bai B, Tian R, Zhu S*, Rao L*, Huang F, Yu G*. Supramolecular engineering of cell membrane vesicles for cancer immunotherapy. Science Bulletin. 2022; 67(18):1898-1909. (IF 20.577)
84. Zhang C-S#, Li M#, Wang Y#, Li X#, Zong Y#, Long S, Zhang M, Feng J-W, Wei X, Liu Y-H, Zhang B, Wu J, Zhang C, Lian W, Ma T, Tian X, Qu Q, Yu Y, Xiong J, Liu D-T, Wu Z, Zhu M, Xie C, Wu Y, Xu Z, Yang C, Chen J, Huang G, He Q, Huang X, Zhang L, Sun X, Liu Q, Ghafoor A, Gui F, Zheng K, Wang W, Wang Z-C, Yu Y, Zhao Q, Lin S-Y, Wang Z-X, Piao H-L, Deng X*, Lin S-C*. The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nature Metabolism. 2022;4(10):1369-1401. (IF 19.865)
85. Zheng Z-Z#, Xia L#, Hu G-S#, Liu J-Y, Hu Y-H, Chen Y-J, Peng J-Y, Liu W*, Z W-J*. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer. Nucleic Acids Research. 2022;50(18):10230-10248. (IF 19.16)
86. Chen BQ, Zhao Y, Zhang Y, Pan YJ, Xia HY, Kankala RK*, Wang SB, Liu G, Chen AZ*. Immune-regulating camouflaged nanoplatforms: A promising strategy to improve cancer nano-immunotherapy. Bioactive Materials. 2023;21:1-19. (IF 16.8737)
87. Fu Q, Feng H, Liu L, Li Z, Li J, Hu J, Hu C, Yan X, Yang H, Song J*. Spatiotemporally Controlled Formation and Rotation of Magnetic Nanochains In Vivo for Precise Mechanotherapy of Tumors. Angewandte Chemie International Edition. 2022;61(51):e202213319. (IF 16.823)
88. Tian M, Wu S, Wang YX*, Liu L, Zhang J, Shen H, Lu Y, Bao H, Huang Q. Associations of environmental phthalate exposure with male steroid hormone synthesis and metabolism: An integrated epidemiology and toxicology study. Journal of Hazardous Materials. 2022;436:129213. (IF 14.224)
89. Liu R, Zhong Y, Chen R, Chu C, Liu G, Zhou Y, Huang Y, Fang Z*, Liu H*. m(6)A reader hnRNPA2B1 drives multiple myeloma osteolytic bone disease. Theranostics. 2022; 12(18):7760-7774. (IF 11.600)
90. Wang P#, Zhou R#, Zhou R#, Li W, Weerasinghe J, Chen S, Rehm BHA, Zhao L, Frentiu FD, Zhang Z, Yan K, Lor M, Suhrbier A, Richard DJ, Thompson EW, Ostrikov KK, Dai X*. Cold atmospheric plasma for preventing infection of viruses that use ACE2 for entry. Theranostics. 2022;12(6):2811-2832. (IF 11.5554)
91. Chu W#, Xu H#, Wang Y#, Xie Y, Chen YL, Tan X, Huang C, Wang G, Wang Q, Luo W, Xia N, Geng M, Xie Z*, Wang C*. HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities. Clinical and Translational Medicine. 2022;12(4):e791. (IF 11.492)
92. Tan C#, Meng L#, Lv M#, He X#, Sha Y#, Tang D#, Tan Y, Hu T, He W, Tu C, Nie H, Zhang H, Du J, Lu G, Fan LQ, Cao Y, Lin G*, Tan YQ*. Bi-allelic variants in DNHD1 cause flagellar axoneme defects and asthenoteratozoospermia in humans and mice. The American Journal of Human Genetics. 2022;109(1):157-171. (IF 11.0255)
93. Men X, Geng X, Zhang Z, Chen H, Du M, Chen Z, Liu G, Wu C, Yuan Z*. Biomimetic semiconducting polymer dots for highly specific NIR-II fluorescence imaging of glioma. Materials Today Bio. 2022; 16:100383. (IF 10.761)
94. Tian M#, Morais CLM#, Shen H#, Pang W, Xu L, Huang Q, Martin FL*. Direct identification and visualisation of real-world contaminating microplastics using Raman spectral mapping with multivariate curve resolution-alternating least squares. Journal of Hazardous Materials. 2022; 422:126892. (IF 10.588)
95. Yuan P#, Tan Y#, Yang L#, Aruffo E#, Ogden NH, Yang G*, Lu H, Lin Z, Lin W, Ma W, Fan M, Wang K, Shen J, Chen T, Zhu H*. Assessing the mechanism of citywide test-trace-isolate Zero-COVID policy and exit strategy of COVID-19 pandemic. Infectious Diseases of Poverty. 2022;11(1):104. (IF 10.485)
96. Ye Z, Fan Y, Zhu T, Cao D, Hu X, Xiang S, Li J, Guo Z, Chen X*, Tan K*, Zheng N*. Preparation of Two-Dimensional Pd@Ir Nanosheets and Application in Bacterial Infection Treatment by the Generation of Reactive Oxygen Species. ACS Applied Materials & Interfaces. 2022; 23194–23205. (IF 10.383)
97. Zhang H, Yin L*, Mao L, Mei S, Chen T, Liu K, Feng S. Combinational Recommendation of Vaccinations, Mask-Wearing, and Home-Quarantine to Control Influenza in Megacities: An Agent-Based Modeling Study With Large-Scale Trajectory Data. Frontiers in Public Health. 2022;10:883624. (IF 6.461) SSCI
